Synapse - David Hyman

Results (21)

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Journal Article

Drilon, A.; Eaton, A. A.; Schindler, K.; Gounder, M. M.; Spriggs, D. R.; Harris, P.; Ivy, S. P.; Iasonos, A.; Lacouture, M. E.; Hyman, D. M.
Cancer (2016)

Fulltext@MSK | Save

What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Journal Article

Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of related and unrelated toxicities

Journal Article

Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E. G.; Drilon, A.; Vulih, D.; Smith, G. L.; Ivy, S. P.; Spriggs, D. R.; Hyman, D. M.
Clinical Cancer Research (2016)

Fulltext@MSK | Save

Phase I trial of the HSP-90 inhibitor PU-H71

Meeting Abstract

Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities

Meeting Abstract

Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)